Apellis Pharmaceuticals (APLS) to Release Quarterly Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) will announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.73). The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.50) EPS. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Apellis Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ APLS opened at $47.46 on Friday. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. The company’s 50 day moving average price is $55.71 and its 200-day moving average price is $57.45. The company has a market capitalization of $5.76 billion, a P/E ratio of -10.59 and a beta of 0.97.

Wall Street Analyst Weigh In

A number of brokerages have commented on APLS. Wedbush cut their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Raymond James raised their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. JPMorgan Chase & Co. lifted their target price on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. HC Wainwright restated a “buy” rating and set a $92.00 price target on shares of Apellis Pharmaceuticals in a report on Friday, April 26th. Finally, Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating for the company in a research report on Monday, April 29th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.40.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel David O. Watson sold 781 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $52,928.37. Following the transaction, the general counsel now owns 103,390 shares in the company, valued at $7,006,740.30. The disclosure for this sale can be found here. Insiders sold a total of 376,427 shares of company stock valued at $23,169,639 over the last three months. Corporate insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).